Section Arrow
MAIA.NYSE-M
- MAIA Biotechnology
Quotes are at least 15-min delayed:2026/07/21 18:00 EDT
After Hours
Last
 1.3199
-0.0101 (-0.76%)
Bid
1.31
Ask
1.32
High 1.33 
Low 1.31 
Volume 166 
Regular Hours (Closed)
Last
 1.33
+0.05 (+3.91%)
Day High 
1.35 
Prev. Close
1.28 
1-M High
1.53 
Volume 
359.31K 
Bid
1.31
Ask
1.32
Day Low
1.281 
Open
1.3 
1-M Low
1.27 
Market Cap 
77.82M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.41 
20-SMA 1.41 
50-SMA 1.36 
52-W High 3.19 
52-W Low 0.87 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.68/-0.46
Enterprise Value
77.82M
Balance Sheet
Book Value Per Share
0.46
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
JUNSJupiter Neurosciences Inc0.1697+0.0047+2.85%-- 
After Hours 0.1649 -0.0048 -2.83%
VIVSVivoSim Lab Inc0.45-0.0549-10.87%0.47PE
After Hours 0.477 +0.027 +6.00%
IOVAIovance Biotherapeutics5.48+0.46+9.16%-- 
After Hours 5.5 +0.02 +0.36%
GOSSGossamer Bio0.1548+0.0138+9.79%-- 
After Hours 0.1547 -0.0001 -0.06%
RXRXRecursion Pharmaceuticals3.08+0.19+6.57%-- 
After Hours 3.0701 -0.0099 -0.32%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.